Antihemophilic Factor |

June 12, 2014
by PharmaReviews
0 comments

FDA Approves Eloctate – first Antihemophilic Factor, Fc Fusion Protein for Patients with Hemophilia A

The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment designed to require less frequent injections when used … Continue reading →